Please check your internet connection and try again.
# Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep
## Overview
Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep is a combination antiviral medication used for the treatment of chronic hepatitis C virus (HCV) infection. It contains two direct-acting antiviral agents.
## Primary Indications
Treatment of chronic hepatitis C virus (HCV) infection in adults. The specific genotype and treatment history will dictate the recommended regimen and duration.
## Adult Dosing
Dosing depends on the HCV genotype and patient's prior treatment experience. Refer to current guidelines (e.g., AASLD/IDSA) for specific recommendations. A common regimen involves one tablet (containing fixed-dose sofosbuvir and velpatasvir) taken orally once daily. Treatment duration is typically 8 to 12 weeks, but can be extended in certain cases.
## Pediatric Dosing
Established pediatric dosing information is limited for this specific combination product. Refer to specific pediatric guidelines or consult a specialist.
## Dose Adjustments
No dose adjustment is required for patients with mild to moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m²). Data is insufficient for patients with severe renal impairment or end-stage renal disease. Dose adjustments are generally not needed for hepatic impairment, but caution is advised in decompensated cirrhosis.
## Contraindications
* Known hypersensitivity to the active ingredients or any excipients.
* Concomitant use with strong P-glycoprotein (P-gp) inducers (e.g., rifampin, St. John's wort, carbamazepine) as they can significantly reduce plasma concentrations of the components.
## Adverse Effects
Common adverse effects include headache, fatigue, nausea, insomnia, and anemia. Less common but serious adverse effects may include bradycardia (especially when co-administered with amiodarone), and potential for reactivation of Hepatitis B virus (HBV) infection.
## Key Drug Interactions
* **Amiodarone:** Increased risk of severe symptomatic bradycardia. Avoid concomitant use if possible, or use with caution and close monitoring.
* **Strong P-gp inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's wort):** Can significantly decrease efficacy. Avoid concomitant use.
* **Antacids, H2 receptor antagonists, proton pump inhibitors:** May affect absorption. Administer these agents at least 4 hours apart from Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep.
## Monitoring
* HCV RNA levels to assess treatment response and confirm sustained virologic response (SVR) 12 weeks after completion of therapy.
* Liver function tests.
* Hemoglobin (especially if co-administered with ribavirin, although this combination may not be used with Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520voihep).
* HBV DNA testing prior to initiating therapy to screen for co-infection.
## Clinical Pearls
* Always confirm the specific HCV genotype and consult current treatment guidelines for the most appropriate regimen and duration.
* Ensure patients are screened for HBV co-infection prior to treatment, as direct-acting antivirals can lead to HBV reactivation.
* Educate patients on the importance of adherence for optimal treatment outcomes.
* Be aware of potential drug interactions, particularly with cardiac medications like amiodarone and herbal supplements like St. John's wort.
This information is intended for healthcare professionals. Please consult the official prescribing information and relevant clinical guidelines for complete details before prescribing.
